Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | STAT6 | P42226 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20879798 | 0.83 | CHRM5 (0.38) | CHRM5CHRM3ALDH1A1 | |
| SCHEMBL29318723 | 0.83 | CHRM5 (0.45) | CHRM5CHRM3NPC1GAAPOLB | |
| SCHEMBL24710260 | 0.81 | CHRM5 (0.37) | CHRM5CHRM3GAAPOLBCYP3A4 | |
| SCHEMBL24663287 | 0.79 | SIGMAR1 (0.36) | CHRM5CHRM3ALDH1A1SIGMAR1 | |
| SCHEMBL29328099 | 0.74 | TP53 (0.39) | CHRM5CHRM3KMT2AMEN1SIGMAR1 | |
| SCHEMBL7721235 | 0.74 | CHRM5 (0.72) | CHRM5CHRM3NPC1GAAPOLB | |
| SCHEMBL29342747 | 0.73 | SIGMAR1 (0.32) | CHRM5CHRM3SIGMAR1 | |
| SCHEMBL13417680 | 0.72 | CHRM5 (0.70) | CHRM5CHRM3NPC1GAAPOLB | |
| SCHEMBL22278103 | 0.71 | GAA (0.40) | CHRM5CHRM3NPC1GAAPOLB | |
| SCHEMBL21100253 | 0.70 | ALDH1A1 (0.34) | CHRM5CHRM3NPC1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2018045084-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CHRM5 4859/4885CHRM3 4787/4885NPC1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.